Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies

Conclusions: Once-daily IND/GLY/MF and IND/MF high-dose were well-tolerated in Japanese patients with inadequately controlled asthma. No unexpected safety findings were observed.PMID:35348408 | DOI:10.1080/02770903.2022.2056048

Source: Journal of Asthma - March 29, 2022 Category: Respiratory Medicine Authors: Hironori Sagara Peter D'Andrea Ana-Maria Tanase Abhijit Pethe Yukina Tanaka Kazutaka Matsuo Motoi Hosoe Yoichi Nakamura Source Type: research